ShankerValleau Wealth Advisors Inc. acquired a new stake in Johnson & Johnson (NYSE:JNJ – Get Rating) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 1,219 shares of the company’s stock, valued at approximately $215,000. Johnson & Johnson makes up 0.1% of ShankerValleau Wealth Advisors Inc.’s holdings, making the stock its 18th largest holding.
A number of other hedge funds have also bought and sold shares of JNJ. Glassy Mountain Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $35,000. TD Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $48,000. Cowa LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $58,000. Legend Financial Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $59,000. Finally, Adirondack Retirement Specialists Inc. purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $67,000. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.35% of the company’s stock.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The firm had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. During the same quarter in the previous year, the company earned $2.13 earnings per share. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.5 EPS for the current year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s payout ratio is 67.06%.
Analysts Set New Price Targets
JNJ has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. SVB Leerink dropped their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Citigroup lifted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. Finally, Atlantic Securities lifted their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $174.73.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- What is the Consumer Staples Sector?
- What is a Consumer Staples Index Fund?
- Bitcoin Might Better Than Bitcoin Stocks and ETFs,
- GameStop Shares Surge On Surprise Profit
- Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
